

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Emma Suzanne Cohen</td> <td>04/23/2007</td> </tr> <tr> <td>Paula Rosamund Harrison</td> <td>04/19/2007</td> </tr> <tr> <td>Ralph Raymond Minter</td> <td>04/18/2007</td> </tr> <tr> <td>Matthew Alexander Sleeman</td> <td>04/16/2007</td> </tr> </tbody> </table>		Name	Execution Date	Emma Suzanne Cohen	04/23/2007	Paula Rosamund Harrison	04/19/2007	Ralph Raymond Minter	04/18/2007	Matthew Alexander Sleeman	04/16/2007
Name	Execution Date										
Emma Suzanne Cohen	04/23/2007										
Paula Rosamund Harrison	04/19/2007										
Ralph Raymond Minter	04/18/2007										
Matthew Alexander Sleeman	04/16/2007										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Cambridge Antibody Technology Limited</td> </tr> <tr> <td>Street Address:</td> <td>Milstein Building, Granta Park</td> </tr> <tr> <td>City:</td> <td>Cambridge</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>CB21 6GH</td> </tr> </table>		Name:	Cambridge Antibody Technology Limited	Street Address:	Milstein Building, Granta Park	City:	Cambridge	State/Country:	UNITED KINGDOM	Postal Code:	CB21 6GH
Name:	Cambridge Antibody Technology Limited										
Street Address:	Milstein Building, Granta Park										
City:	Cambridge										
State/Country:	UNITED KINGDOM										
Postal Code:	CB21 6GH										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13941409</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13941409						
Property Type	Number										
Application Number:	13941409										
CORRESPONDENCE DATA											
<p>Fax Number: 5035955301 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i></p> <p>Phone: (503) 595-5300 Email: tanya.harding@klarquist.com Correspondent Name: Tanya M. Harding, Ph.D. Address Line 1: 121 SW Salmon Street Address Line 2: One World Trade Center, Suite 1600 Address Line 4: Portland, OREGON 97204</p>											
ATTORNEY DOCKET NUMBER:	7029-74191-04 TMH										
NAME OF SUBMITTER:	Tanya M. Harding, Ph.D.										
Signature:	/Tanya M. Harding/										

PATENT

Date:

07/30/2013

Total Attachments: 12

source=74191-04_assign_Cambridge#page1.tif
source=74191-04_assign_Cambridge#page2.tif
source=74191-04_assign_Cambridge#page3.tif
source=74191-04_assign_Cambridge#page4.tif
source=74191-04_assign_Cambridge#page5.tif
source=74191-04_assign_Cambridge#page6.tif
source=74191-04_assign_Cambridge#page7.tif
source=74191-04_assign_Cambridge#page8.tif
source=74191-04_assign_Cambridge#page9.tif
source=74191-04_assign_Cambridge#page10.tif
source=74191-04_assign_Cambridge#page11.tif
source=74191-04_assign_Cambridge#page12.tif

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Assignor'

Emma Suzanne COHEN

Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge
CB21 6GH, UNITED KINGDOM

2 'The Assignee'

Cambridge Antibody Technology Limited

Milstein Building, Granta Park, Cambridge CB21 6GH, UNITED KINGDOM

Recitals:

(A) The Assignor is the inventor or a joint inventor of the invention or inventions entitled **Binding Member for GM-CSF Receptor**.

("the Invention") for which International PCT Application No. PCT/GB2007/001108 ("the PCT Application") and US Patent Application No. 11/692,008 ("the US Application") have been filed.

(B) In pursuance of an agreement made between the parties before the PCT Application and US Application were filed the Assignor has agreed to assign to the Assignee for the consideration hereinafter mentioned all his rights title and interest in to and under the Invention, the US Application and the PCT Application for all countries designated therein [including (without limitation) the United States of America]

Operative provisions:

In consideration for the payment of £1.00 by the Assignee to the Assignor the receipt and sufficiency of which is hereby acknowledged by the Assignor:

1 The Assignor hereby sells and assigns to the Assignee absolutely and free from incumbrances:

1.1 all his rights title and interest in Canada and the United States and all other countries of the world in to and under the Invention, the US Application and the PCT Application and all national and regional phases thereof and any and all divisionals, continuations and continuations-in-part of any of the aforesaid applications and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as he may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or its successors or assigns;

1.3 all such rights as he may have to claim priority from all patent applications (if any) from

which priority is claimed in the PCT Application and the US Application in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the PCT Application and the US Application;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made.

2 The Assignor hereby GRANTS the firm of Mewburn Ellis LLP the power to insert in the Schedule to this Assignment any further identification of any patent applications in Canada or the United States or any other countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other Patent Office for recordation of this document. It is understood and agreed that the Assignee's attorneys Mewburn Ellis LLP have not represented the Assignor and will continue to represent only the Assignee and its successors in title with respect to the Invention and all patent applications relating thereto.

3 The Assignor hereby UNDERTAKES that at the request and cost of the Assignee or its successors or assigns he will at all times hereafter promptly do all such acts and execute all such documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any application for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.

5 This assignment and undertaking shall be binding upon the Assignor's heirs, executors, administrators, successors and/or assigns and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

AS WITNESS the signatures of (or of duly authorised officers of) the parties hereto

SCHEDULE

International patent application no. PCT/GB2007/001108 filed on 27 March 2007

US patent application no. US 11/692,008 filed on 27 March 2007


SIGNED by) COHEN, Emma Suzanne

the ASSIGNOR)


at: CAMBRIDGE, UK)

on: 23rd April 2007)

in the presence of:)

Signature: 

Witness

Signature: 

Name: ALISON MCGHEE

Address: CAMBRIDGE ANTIBODY TECHNOLOGY, GRANTA PARK,
CAMBRIDGE, CB21 6GH


SIGNED for and on behalf of) Cambridge Antibody Technology Limited

the ASSIGNEE)

at: Cambridge, UK)

on: 26 April 2007)

in the presence of:)

Signature: 

Name: ADRIAN KEMP

Witness

Signature: 

Name: CAROL ASHMAN

Address: CAT, Milstein Building, Granta Park, Cambridge CB2 6GH, UK

Position: COMPANY SECRETARY

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Assignor'

Paula Rosamund HARRISON

Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge
CB21 6GH, UNITED KINGDOM

2 'The Assignee'

Cambridge Antibody Technology Limited

Milstein Building, Granta Park, Cambridge CB21 6GH, UNITED KINGDOM

Recitals:

(A) The Assignor is the inventor or a joint inventor of the invention or inventions entitled **Binding Member for GM-CSF Receptor**.

("the Invention") for which International PCT Application No. PCT/GB2007/001108 ("the PCT Application") and US Patent Application No. 11/692,008 ("the US Application") have been filed.

(B) In pursuance of an agreement made between the parties before the PCT Application and US Application were filed the Assignor has agreed to assign to the Assignee for the consideration hereinafter mentioned all his rights title and interest in to and under the Invention, the US Application and the PCT Application for all countries designated therein [including (without limitation) the United States of America]

Operative provisions:

In consideration for the payment of £1.00 by the Assignee to the Assignor the receipt and sufficiency of which is hereby acknowledged by the Assignor:

1 The Assignor hereby sells and assigns to the Assignee absolutely and free from incumbrances:

1.1 all his rights title and interest in Canada and the United States and all other countries of the world in to and under the Invention, the US Application and the PCT Application and all national and regional phases thereof and any and all divisionals, continuations and continuations-in-part of any of the aforesaid applications and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as he may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or its successors or assigns;

1.3 all such rights as he may have to claim priority from all patent applications (if any) from

which priority is claimed in the PCT Application and the US Application in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the PCT Application and the US Application;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made.

2 The Assignor hereby GRANTS the firm of Mewburn Ellis LLP the power to insert in the Schedule to this Assignment any further identification of any patent applications in Canada or the United States or any other countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other Patent Office for recordation of this document. It is understood and agreed that the Assignee's attorneys Mewburn Ellis LLP have not represented the Assignor and will continue to represent only the Assignee and its successors in title with respect to the Invention and all patent applications relating thereto.

3 The Assignor hereby UNDERTAKES that at the request and cost of the Assignee or its successors or assigns he will at all times hereafter promptly do all such acts and execute all such documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any application for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.

5 This assignment and undertaking shall be binding upon the Assignor's heirs, executors, administrators, successors and/or assigns and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

AS WITNESS the signatures of (or of duly authorised officers of) the parties hereto

SCHEDULE

International patent application no. PCT/GB2007/001108 filed on 27 March 2007

US patent application no. US 11/692,008 filed on 27 March 2007

SIGNED by) HARRISON, Paula Rosamund
the ASSIGNOR)
at: CAMBRIDGE, UK)
on: 19th April 2007) Signature: PRL
in the presence of:)

Witness

Signature: Alison McGhee

Name: ALISON MCGHEE

Address: CAMBRIDGE ANTIBODY TECHNOLOGY, MILSTEIN BUILDING,
GRANTA PARK, CAMBRIDGE, CB21 6GH, UK

SIGNED for and on behalf of) Cambridge Antibody Technology Limited
the ASSIGNEE)
at: Cambridge, UK)
on: 26 April 2006) Signature: ANKCP
in the presence of:) Name: ADRIAN KEMP

Witness) Position: COMPANY SECRETARY

Signature: CAmer

Name: CAROL ASHMAN

Address: CAT, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Assignor'

Ralph Raymond MINTER

Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge
CB21 6GH, UNITED KINGDOM

2 'The Assignee'

Cambridge Antibody Technology Limited

Milstein Building, Granta Park, Cambridge CB21 6GH, UNITED KINGDOM

Recitals:

(A) The Assignor is the inventor or a joint inventor of the invention or inventions entitled **Binding Member for GM-CSF Receptor**.

("the Invention") for which International PCT Application No. PCT/GB2007/001108 ("the PCT Application") and US Patent Application No. 11/692,008 ("the US Application") have been filed.

(B) In pursuance of an agreement made between the parties before the PCT Application and US Application were filed the Assignor has agreed to assign to the Assignee for the consideration hereinafter mentioned all his rights title and interest in to and under the Invention, the US Application and the PCT Application for all countries designated therein [including (without limitation) the United States of America]

Operative provisions:

In consideration for the payment of £1.00 by the Assignee to the Assignor the receipt and sufficiency of which is hereby acknowledged by the Assignor:

1 The Assignor hereby sells and assigns to the Assignee absolutely and free from incumbrances:

1.1 all his rights title and interest in Canada and the United States and all other countries of the world in to and under the Invention, the US Application and the PCT Application and all national and regional phases thereof and any and all divisionals, continuations and continuations-in-part of any of the aforesaid applications and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as he may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or its successors or assigns;

1.3 all such rights as he may have to claim priority from all patent applications (if any) from

which priority is claimed in the PCT Application and the US Application in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the PCT Application and the US Application;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made.

2 The Assignor hereby GRANTS the firm of Mewburn Ellis LLP the power to insert in the Schedule to this Assignment any further identification of any patent applications in Canada or the United States or any other countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other Patent Office for recordation of this document. It is understood and agreed that the Assignee's attorneys Mewburn Ellis LLP have not represented the Assignor and will continue to represent only the Assignee and its successors in title with respect to the Invention and all patent applications relating thereto.

3 The Assignor hereby UNDERTAKES that at the request and cost of the Assignee or its successors or assigns he will at all times hereafter promptly do all such acts and execute all such documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any application for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.


5 This assignment and undertaking shall be binding upon the Assignor's heirs, executors, administrators, successors and/or assigns and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

AS WITNESS the signatures of (or of duly authorised officers of) the parties hereto

SCHEDULE

International patent application no. PCT/GB2007/001108 filed on 27 March 2007

US patent application no. US 11/692,008 filed on 27 March 2007


SIGNED by) MINTER, Ralph Raymond
the ASSIGNOR)
at: CAMBRIDGE, UK)
on: 18th April 2007) Signature: 
in the presence of:)

Witness

Signature: 

Name: ALISON MCGHEE

Address: CAMBRIDGE ANTIBODY TECHNOLOGY, MILSTEIN BUILDING,
GRANTA PARK, CAMBRIDGE, CB21 6GH, UK

SIGNED for and on behalf of) Cambridge Antibody Technology Limited
the ASSIGNEE)
at: Cambridge, UK)
on: 26 April 2007) Signature: 
in the presence of:) Name: ADRIAN KEMP

Witness

Signature: 

Name: CAROL ASHMAN

Address: CAT, Milstein Building, Granta Park, Cambridge CB21 6GH

Position: COMPANY SECRETARY

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Assignor'

Matthew Alexander SLEEMAN

Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge
CB21 6GH, UNITED KINGDOM

2 'The Assignee'

Cambridge Antibody Technology Limited

Milstein Building, Granta Park, Cambridge CB21 6GH, UNITED KINGDOM

Recitals:

(A) The Assignor is the inventor or a joint inventor of the invention or inventions entitled **Binding Member for GM-CSF Receptor**.

("the Invention") for which International PCT Application No. PCT/GB2007/001108 ("the PCT Application") and US Patent Application No. 11/692,008 ("the US Application") have been filed.

(B) In pursuance of an agreement made between the parties before the PCT Application and US Application were filed the Assignor has agreed to assign to the Assignee for the consideration hereinafter mentioned all his rights title and interest in to and under the Invention, the US Application and the PCT Application for all countries designated therein [including (without limitation) the United States of America]

Operative provisions:

In consideration for the payment of £1.00 by the Assignee to the Assignor the receipt and sufficiency of which is hereby acknowledged by the Assignor:

1 The Assignor hereby sells and assigns to the Assignee absolutely and free from incumbrances:

1.1 all his rights title and interest in Canada and the United States and all other countries of the world in to and under the Invention, the US Application and the PCT Application and all national and regional phases thereof and any and all divisionals, continuations and continuations-in-part of any of the aforesaid applications and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as he may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or its successors or assigns;

1.3 all such rights as he may have to claim priority from all patent applications (if any) from

which priority is claimed in the PCT Application and the US Application in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the PCT Application and the US Application;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made.

2 The Assignor hereby GRANTS the firm of Mewburn Ellis LLP the power to insert in the Schedule to this Assignment any further identification of any patent applications in Canada or the United States or any other countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other Patent Office for recordation of this document. It is understood and agreed that the Assignee's attorneys Mewburn Ellis LLP have not represented the Assignor and will continue to represent only the Assignee and its successors in title with respect to the Invention and all patent applications relating thereto.

3 The Assignor hereby UNDERTAKES that at the request and cost of the Assignee or its successors or assigns he will at all times hereafter promptly do all such acts and execute all such documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any application for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.

5 This assignment and undertaking shall be binding upon the Assignor's heirs, executors, administrators, successors and/or assigns and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

AS WITNESS the signatures of (or of duly authorised officers of) the parties hereto

SCHEDULE

International patent application no. PCT/GB2007/001108 filed on 27 March 2007

US patent application no. US 11/692,008 filed on 27 March 2007

SIGNED by) SLEEMAN, Matthew Alexander

the ASSIGNOR)


at: CAMBRIDGE, UK)

on: 16th April 2007)

Signature: 

in the presence of:)

Witness

Signature: 

Name: Sarah Thompson

Address: CAT, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

SIGNED for and on behalf of) Cambridge Antibody Technology Limited

the ASSIGNEE)

at: Cambridge, UK)

on: 26 April 2007)

Signature: 

in the presence of:)

Name: ADRIAN KEMP

Witness

Signature: 

Position: COMPANY SECRETARY

Name: CAROL ASHMAN

Address: CAT, Milstein Building, Granta Park, Cambridge CB21 6GH, UK